Objectives: To evaluate the in vivo antibacterial efficacy of nemonoxacin, a novel C8-methoxy non-fluorinated quinolone in murine systemic and local infection models.
Introduction
Nemonoxacin (TG-873870) (TaiGen Biopharmaceuticals Co. Ltd, Beijing, China) is a novel C8-methoxy non-fluorinated quinolone. The C8-methoxy substituents have been associated with an improved spectrum of activity, including increased activity against Gram-positive cocci, and reduced mutant selection. 1, 2 The removal of the fluorine residue could reduce the incidence of toxic side effects. 3 In vitro activity studies of nemonoxacin demonstrated that it had higher activity than that of levofloxacin and moxifloxacin against Gram-positive cocci, including methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae and Enterococcus faecalis, while its activity against Gram-negative bacilli was similar to that of levofloxacin and moxifloxacin. 4, 5 In this study, the efficacy of nemonoxacin was evaluated in vivo in mouse systemic and local infection models using levofloxacin as a comparator.
Materials and methods

Antimicrobial agents
Nemonoxacin (TG-873870) in the form of malate salt (TG-875649) (C 24 H 32 N 3 O 9.5 , mol. wt 514.53, purity 99.2%) was obtained from TaiGen Biopharmaceuticals Co. Ltd (Beijing, China). Levofloxacin (purity 97.3%) was purchased from the National Pharmaceutical and Biological Products Control Institute (Beijing, China). The compounds were dissolved in sterile water and the concentrations were calculated based on their active moiety.
Microorganisms
S. aureus ATCC 29213 (methicillin-susceptible S. aureus, MSSA), S. pneumoniae ATCC 49619 (penicillin-intermediate S. pneumoniae, PISP), E. faecalis ATCC 29212 and Escherichia coli ATCC 25922 were standard isolates from ATCC (Manassas, VA, USA). S. aureus 0705 (MRSA), Staphylococcus capitis 0687 (methicillin-and levofloxacinresistant S. capitis, levofloxacin-resistant MRSC), S. pneumoniae 0518 (penicillin-resistant S. pneumoniae, PRSP), S. pneumoniae 0613 (PRSP), E. faecalis 4041 (vancomycin-resistant Enterococcus, VRE), Klebsiella pneumoniae 0607, E. coli 0635, E. coli 0638 and E. coli 0526 were clinical isolates. Bacteria were stored at 2808C until use.
Laboratory animals
CD-1 ICR mice were purchased from Vital River Laboratories (Beijing, China) and acclimatized for 1 day prior to use. All animals were housed in cages (five animals of the same sex per cage) under constant temperature (228C) and humidity, and had free access to food and water throughout the study, except for the mouse ascending urinary tract infection model during the water restriction period. All studies with animals were approved by the Animal Research Committee of the Institute of Medicinal Biotechnology (Beijing, China).
Mouse systemic infection model
The in vivo efficacy of nemonoxacin against mouse systemic infections versus that of levofloxacin was evaluated with two strains of S. aureus, one strain of S. capitis, three strains of S. pneumoniae, two strains of E. faecalis and three strains of E. coli (see Table 1 ). The experiment was carried out according to a previously described method, with modifications. 6 For each isolate infection, CD-1 ICR mice (body weight, 18-22 g) were allocated randomly into 11 groups, with 5 groups (5 doses) for each compound and 1 control group (10 mice per group, 5 males and 5 females). The mice were infected intraperitoneally with 0.5 mL of a bacterial suspension in 5% mucin (100% minimum lethal dose). Nemonoxacin and levofloxacin (saline for the control group) were administered orally 15 min and 6 h after infection. The dose ranges of nemonoxacin were 1.6-4.0 mg/kg for S. aureus and S. capitis infections, 2.4-10.0 mg/kg for S. pneumoniae infections, 5.0-22.6 mg/kg for E. faecalis infections, and 1.6-10.0 mg/kg for E. coli infections. Deaths in each group were recorded daily for 7 days, and the 50% effective dose (ED 50 ) and 95% confidence limits were calculated by probit analysis. 7 
Mouse pulmonary infection model
The therapeutic efficacies of nemonoxacin and levofloxacin in mouse pulmonary infections caused by S. pneumoniae 0613 (PRSP) and K. pneumoniae 0607 were evaluated with CD-1 ICR mice (body weight, 18-22 g; 10 mice per group, 5 males and 5 females) according to published methods, with modifications. 8, 9 Four different doses of nemonoxacin or levofloxacin were used in the experiments for each isolate infection (see Table 2 ). For S. pneumoniae 0613 infection, the mice were first subjected to cyclophosphamide immunocompromise (150 mg/kg/day for 3 days). 10, 11 Then, the mice were anaesthetized with ether and infected intranasally using 50 mL of fresh bacterial suspension in saline (challenge dose, 4.0×10 7 cfu/mouse). Nemonoxacin or levofloxacin was administered orally 6, 12 and 24 h after infection. The mice were sacrificed 28 h after infection and the lungs were removed under sterile conditions. The lungs were homogenized in saline (0.1 g of tissue to a final volume of 1 mL), and viable colony counts were determined after blood agar plates were spread with 0.1 mL of properly diluted homogenates and incubated at 358C for 48 h.
For K. pneumoniae 0607 infection, the mice were infected without immunocompromise. Briefly, the mice were anaesthetized with ether and infected intranasally using 50 mL of bacterial suspension in saline (challenge dose, 1.0×10 7 cfu/mouse). Nemonoxacin or levofloxacin was administered orally 6, 12 and 24 h after infection. The mice were sacrificed 28 h after infection and the lungs were removed under sterile conditions. The lungs were homogenized in saline (0.1 g of tissue to a final volume of 1 mL), and viable colony counts were determined after nutrient agar plates were spread with 0.1 mL of properly diluted homogenates and incubated at 358C for 48 h. The lower detection limit was 2 log cfu/g, which corresponded to the weakest dilution of lung tissue of 10 21 that avoided significant drug carryover. The statistical significance was determined using SPSS 12.0.
Mouse ascending urinary tract infection model
The therapeutic efficacies of nemonoxacin and levofloxacin in mouse ascending urinary tract infection caused by E. coli 0526 were evaluated with CD-1 ICR mice (body weight, 18 -22 g; 10 mice per group, 5 males and 5 females), as previously described with modifications. 12, 13 Four different doses of nemonoxacin or levofloxacin were used (see Table 3 ). The mice were subjected to water restriction for 24 h prior to infection and 6 h after infection. Under pentobarbital sodium (70 mg/kg) anaesthesia, the mice were subjected to bladder exposure by surgery and infected subsequently by injection of 50 mL of bacterial suspension in saline (challenge dose, 3.0×10 7 cfu/mouse) into the bladders. Nemonoxacin or levofloxacin was administered orally 6, 12 and 24 h after infection. The mice were sacrificed 28 h after infection and the kidneys were removed under sterile conditions. The kidneys were homogenized in saline (0.1 g of tissue to a final volume of 1 mL), and viable colony counts were determined after nutrient agar plates were spread with 0.1 mL of properly diluted homogenates and incubated at 358C for 48 h. The lower detection limit was 2 log cfu/g, which corresponded to the weakest dilution of kidney tissue of 10 21 that avoided significant drug carryover. The statistical significance was determined using SPSS 12.0.
Results
Mouse systemic infection model
The MICs, ED 50 s and 95% confidence limits of nemonoxacin and levofloxacin for the tested strains are shown in Table 1 . Nemonoxacin showed potent and broad-spectrum in vivo activity against both Gram-positive (S. aureus, S. capitis, S. pneumoniae and E. faecalis) and Gram-negative (E. coli) isolates. The ED 50 s of nemonoxacin against S. aureus ATCC 29213 (MSSA), S. aureus 0705 (MRSA) and S. capitis 0687 (levofloxacin-resistant MRSC) were 2.08, 2.59 and 2.52 mg/kg, respectively, which were significantly lower (P,0.01) than the corresponding ED 50 s of Li et al.
levofloxacin (5.02, 8.45 and 4.32 mg/kg, respectively). The therapeutic efficacies of nemonoxacin against S. pneumoniae ATCC 49619 (PISP), S. pneumoniae 0518 (PRSP) and S. pneumoniae 0613 (PRSP) infections (ED 50 s of 5.47, 3.68 and 5.28 mg/kg, respectively) were 3-to 5-fold higher (P,0.01) than those of levofloxacin (ED 50 s of 19.14, 19.82 and 22.01 mg/kg, respectively). The activities of nemonoxacin against E. faecalis infection were lower in comparison with its activities against S. aureus, S. capitis and S. pneumoniae infections. The ED 50 s of nemonoxacin against E. faecalis ATCC 29212 and E. faecalis 4041 (VRE) infections were 15.16 and 8.48 mg/kg, respectively, which were significantly lower (P,0.01) than those of levofloxacin (ED 50 s of 26.89 and 17.47 mg/kg, respectively). Nemonoxacin also showed potent activity against Gram-negative isolates, even In vivo activity of nemonoxacin though the efficacy was lower than that of levofloxacin. The ED 50 s of nemonoxacin against E. coli ATCC 25922, E. coli 0635 and E. coli 0638 infections were 3.13, 3.38 and 5.28 mg/kg, respectively, which were 3-to 6-fold higher than those of levofloxacin (P,0.01).
Mouse pulmonary infection model
The results of mouse pulmonary infections treated with nemonoxacin and the reference compound (levofloxacin) are shown in Table 2 . Both nemonoxacin and levofloxacin demonstrated potent activities towards S. pneumoniae 0613 (PRSP) and K. pneumoniae 0607 infections, with most of the tested groups having significantly (P,0.05) decreased colony counts in comparison with the control group. In comparison with levofloxacin at the same dose levels, nemonoxacin exhibited higher activity against S. Table 2) .
Mouse ascending urinary tract infection model
The results of mouse ascending urinary tract infection caused by E. coli 0526 are shown in Table 3 . Nemonoxacin and levofloxacin showed therapeutic efficacies, as all the tested groups of the two compounds showed significant decreases (P,0.05) in kidney colony counts in comparison with the control group. The efficacy of nemonoxacin was lower than that of levofloxacin, demonstrated by the higher colony counts of the nemonoxacin groups than those of the levofloxacin groups at the same dose levels, i.e. log cfu/g values of 4.60 versus 3.47 at the 4 mg/kg dose level (P,0.05) and 4.85 versus 4.00 at the 2 mg/kg dose level (P .0.05).
Discussion
The in vivo activity of nemonoxacin was evaluated in this study using animal models of systemic and local infections. The results from the mouse systemic infection model (Table 1) mirrored the results of in vitro studies. 4, 5 Nemonoxacin demonstrated potent broad-spectrum antibacterial activity against both Gram-positive (S. aureus, S. capitis, S. pneumoniae and E. faecalis, higher than levofloxacin) and Gram-negative (E. coli, lower than levofloxacin) isolates. Nemonoxacin maintained potent antibacterial activity against the tested antibioticresistant isolates (i.e. MRSA, levofloxacin-resistant MRSC, PRSP and VRE, see Table 1 ), which is of great importance considering the problems these isolates have caused in the clinical setting. Of note is that nemonoxacin showed high activity towards levofloxacin-resistant MRSC S. capitis 0687, which suggests that nemonoxacin may be useful against infections caused by levofloxacin-resistant isolates. The mouse local infection models of pulmonary infection (Table 2 ) and ascending urinary tract infection (Table 3) further verified the aforementioned conclusions. Nemonoxacin demonstrated potent efficacies in mouse pulmonary infections caused by S. pneumoniae 0613 and K. pneumoniae 0607, and in mouse ascending urinary tract infection caused by E. coli 0526.
The efficacy of nemonoxacin in mouse pulmonary infection caused by S. pneumoniae 0613 was more potent than that of levofloxacin, although such differences were not significant. In a prior study of nemonoxacin in mouse pulmonary infection caused by S. pneumoniae, the bacterial log killing effect of nemonoxacin was two to six times more potent than that of moxifloxacin at doses of 6.25 -50 mg/kg.
14 Taken together, these data suggested that nemonoxacin was potentially at least as potent as the quinolones in use (levofloxacin, moxifloxacin) for bacterial pneumonia caused by S. pneumoniae.
In conclusion, this study demonstrated nemonoxacin to be a potent agent with broad-spectrum antibacterial activity and significant activity against antibiotic-resistant Gram-positive isolates in vivo. These results support further clinical studies using nemonoxacin. Li et al.
